Pressure Enabled Delivery of SD-101 With Checkpoint Blockade for Primary Liver Tumors

Summary

This is an Open-label, Phase 1b/2 Study of the Pressure-Enabled Hepatic Artery Infusion (HAI) of SD-101, a TLR9 agonist, Alone or in Combination with Intravenous Checkpoint Blockade in Adults with Hepatocellular Carcinoma (HCC) and Intrahepatic Cholangiocarcinoma (ICC).

Timeline

Start

2022-03-02

Primary completion

2024-07-31

Completion

2024-07-31

Outcome

Outcome not reported

Stopped (Enrollment): “The decision was made to terminate the study after the completion of Phase 1b enrollment and not proceed with Phase 2. Trial termination was not due to patient safety or data concerns.”

Drugs

Indications